Insights: Eviscerating patent law?

Matthew Spencer, Partner at Boult Wade Tennant, offers his opinion on the recent guidance from the US Patent and Trademark Office for subject matter eligibility analysis. In an article appearing in Nature’s BioPharma Dealmakers, Matthew questions whether the guidance given threatens to stifle investment and innovation.

Read the article or visit the site.